Women's Dermatologic Society

  By Cather McKay MD, FAAD The past year brought many exciting advances in the field of dermatology. Below is a summary to help you continue providing up-to-date care for your patients. Psoriasis Topical options for psoriasis expanded this year to include tapinarof cream (Vtama), an aryl hydrocarbon receptor–modulating agent, and phosphodiesterase-4 (PDE4) inhibitor roflumilast cream (Zoryve). Additional indications for both are expected in the future. The approval of oral tyrosine kinase 2 (TYK2) inhibitor deucravacitinib was welcomed in September, with trials in psoriatic arthritis ongoing 1 . IL-36 inhibitor spesolimab was also approved in September for generalized pustular psoriasis 2 . Risankizumab (Skyrizi) gained indications for psoriatic arthritis and Crohn’s disease this year. Apremilast (Otezla) is now indicated for all severities of psoriasis as of late 2021 and is in trials for palmoplantar pustulosis (PPP) 3 . Guidelines for psoriatic arthritis were publi...

By Dr. Cather McKay   Our specialty continues to advance despite the pandemic, thanks to the hard work and dedication of researchers and leaders in the field. Here is a summary of some of the biggest news from the last year. COVID-19 COVID-19 still affects our daily lives despite widely available and effective vaccines. As dermatologists, we are tasked with counseling our patients who are treated with disease-modifying drugs. Data published this year suggests that those on methotrexate are more likely to be hospitalized for COVID-19 than those on biologics 1 , apremilast (Otezla®) does not increase the risk of COVID-19 infection 2 , and dupilumab (Dupixent®) is associated with milder infection 3 . At this time, the National Psoriasis Foundation COVID-19 Task Force recommends vaccination and a booster for psoriasis patients. In general, psoriasis treatment should be continued. Those on methotrexate may consider stopping medication for 2 weeks ...